| Accession No. | COA-A26Q2CRB0073 |
| Client | Alpha Nordisk |
| Report Date | 6/9/2026 |
| Product | Cerebrolysin | Lot | A26Q2CRB0073 |
| Chemical | Cerebrolysin | Mfg Date | 2026-Q2 |
| Form | Lyophilized Powder | Exp Date | EXP 05/28 |
| Dose | 10mg | Purity | 99.1% |
| Formula | Complex mixture | Net Content | 9.9 mg |
| Mol. Weight | N/A (complex mixture) | Appearance | White lyophilized powder |
| Test | Method | Specification | Result | Status |
|---|---|---|---|---|
| Appearance | Visual inspection | White lyophilized powder | Conforms | ✓ PASS |
| Identity | ESI-MS (≤5 ppm) | Amino acid profile | Confirmed | ✓ PASS |
| Purity | HPLC-UV (C18, 220 nm) | ≥99.0% | 99.1% | ✓ PASS |
| Related substances | HPLC-UV | ≤1.0% total | <0.9% | ✓ PASS |
| Endotoxin | LAL (gel-clot) | <1.0 EU/mg | <0.5 EU/mg | ✓ PASS |
| Water content | Karl Fischer | <8.0% | <5.2% | ✓ PASS |
| Counterion | Ion chromatography | Acetate (TFA-free) | Acetate | ✓ PASS |
| Sterility | USP <71> visual | No visible contamination | Conforms | ✓ PASS |
HPLC-UV Chromatogram (220 nm)
* Complex neuropeptide mixture. Identity confirmed by amino acid profile analysis.
ESI Mass Spectrum
This Certificate of Analysis is issued by Alpha Nordisk for research and laboratory use documentation. The peptide described is intended exclusively for research and laboratory use. Not for human consumption, clinical, diagnostic, or therapeutic application. Lot traceability and analytical data are maintained by Alpha Nordisk under Danish Formulation Technology standards.